Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real‐life retrospective study
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025
DOI: 10.1111/ddg.15632 ↗Kurz gefasst
Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2025. Verfasst von Dirk Tomsitz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Neoadjuvant Therapy, Ipilimumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Neoadjuvant treatment with ipilimumab and nivolumab has shown efficacy in melanoma patients with nodal metastases in clinical trials. Real world data on neoadjuvant therapies is lacking. Patients and Methods This study investigates the effectiveness of neoadjuvant therapy in a real‐world setting and included all melanoma patients who received combined anti‐CTLA4/PD1 immunotherapy prior to resection. Pathologic and radiologic responses as well as treatment‐related adverse events were assessed, and recurrence‐free survival (RFS) was compared between patients with major pathologic response (mPR) and patients without mPR.
Results
In total, 24 patients were analyzed, including patients with distant metastases and patients with prior adjuvant treatment. Median follow‐up was 21.5 months. Upon histologic assessment, mPR was achieved in 50% (12/24) of the patients, including two patients with lung metastases and three patients who progressed after prior adjuvant anti‐PD1 therapy. Radiologic response after neoadjuvant treatment correlated with mPR. No patient with mPR relapsed during follow‐up (median RFS not reached) compared to six out of 12 patients without mPR (median RFS = 13 months, p = 0.005).
Conclusions
Neoadjuvant treatment with ipilimumab and nivolumab is effective in real‐world patients with different melanoma subtypes, different stages of disease and even advanced primary tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.
- Department of General, Visceral and Transplantation Surgery, LMU University Hospital, LMU Munich, Munich, Germany.
- Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.
- Institute of Pathology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Munich, Germany.
- Department of Oral and Maxillofacial Surgery, University Hospital, LMU Munich, Munich, Germany.
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, LMU Munich, Munich, Germany.
Zitieren
APA
Tomsitz, D., Zimmermann, P., Kunz, W. G., Neumann, J., Siegmund, B. J., Weiss, B. G., Kauke, T., Sienel, W., French, L. E., Klauschen, F., & Heinzerling, L. (2025). Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real‐life retrospective study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15632
Vancouver
Tomsitz D, Zimmermann P, Kunz WG, Neumann J, Siegmund BJ, Weiss BG, et al. Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real‐life retrospective study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025. doi:10.1111/ddg.15632
BibTeX
@article{Tomsitz2025,
author = {Tomsitz, Dirk and Zimmermann, Petra and Kunz, Wolfgang G and Neumann, Jens and Siegmund, Birte J and Weiss, Bernhard G and Kauke, Teresa and Sienel, Wulf and French, Lars E and Klauschen, Frederick and Heinzerling, Lucie},
title = {Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real‐life retrospective study},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2025},
doi = {10.1111/ddg.15632}
}
EUVIMED